J Vet Sci.  2007 Sep;8(3):263-267. 10.4142/jvs.2007.8.3.263.

Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats

Affiliations
  • 1Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Konkuk University, Seoul 143-701, Korea. hshin@konkuk.ac.kr

Abstract

The primary objective of this study was to compare thepharmacokinetics of a new anti-human immunodeficiencyvirus agent 1-(2-amino-pyridin-4-ylmethyl)-6-(3,5-dimethyl-benzoyl)-5-isopropyl-1H-pyrimidine-2,4-dione (VP-0502)with its amino acid prodrug alanine amide of VP-0502(VP-0502AL), following intravenous and oral administrationsto rats. The plasma concentrations of both analytes wereanalyzed via high-performance liquid chromatographycoupled with photodiode-array detection (HPLC-DAD).When VP-0502 was intravenously administered at 20mg/kg, the analyte appeared in low levels with an AUC of 0.3microg.h/ml, and C0 of 0.2microg/ml in plasma. However, boththe prodrug VP-0502AL and its metabolite VP-0502 appearedat comparatively higher levels following intravenousinjection of VP-0502AL at the same dose. VP-0502AL'spharmacokinetic parameters were Vd: 4.6 l/kg; AUC:3microg.h/ml; t1/2: 0.5h; C0: 6microg/ml; CLtot: 7l/h/kg; andMRT: 0.6h. Following oral administration of VP-0502(100mg/kg), it was not detectable in plasma (<50ng/ml),while after the oral administration of VP-0502AL, VP-0502 was quantitatively detected as an active metabolite forthe first 7h, with a maximum plasma concentration(Cmax) of 0.8microg/ml, and an area under the concentration-time curve (AUC) of 2microg.h/ml. The oral pharmacokineticparameters of VP-0502AL were calculated to be: maximumconcentration time (tmax) 2.7h; Cmax 0.2microg/ml; eliminationhalf-life (t1/2): 0.8h; and AUC 0.5microg.h/ml. Overall thefindings indicate that VP-0502AL has a favorable pharmaco-kinetic profile as a prodrug with rapid transformationinto the active metabolite, and that the attachment of theamino acid alanine to VP-0502 is an effective approach toimprove its oral bioavailability. VP-0502AL is predictedto become a new highly bioavailable anti-AIDS drugcandidate and/or lead compound.

Keyword

anti-HIV; bioavailability; pharmacokinetics; pro-drug

MeSH Terms

Administration, Oral
Alanine/*analogs & derivatives/pharmacokinetics
Aminopyridines/*pharmacokinetics
Animals
Anti-HIV Agents/administration & dosage/blood/*pharmacokinetics
Area Under Curve
Biological Availability
Half-Life
Injections, Intravenous
Male
Prodrugs/administration & dosage/*pharmacokinetics
Rats
Rats, Sprague-Dawley
Uracil/*analogs & derivatives/pharmacokinetics

Figure

  • Fig. 1 Structure of alanine amide (AL) of 1-(2-amino-pyridin-4-ylmethyl)-6-(3,5-dimethyl-benzoyl)-5-isopropyl-1H-pyrimidine-2,4-dione (VP-0502).

  • Fig. 2 Chromatograms of VP-0502 and VP-0502AL detected in rat plasma following oral administration of VP-0502AL at a dose of 100 mg/kg.

  • Fig. 3 Semilogarithmic graph depicting the plasma concentration time curve of VP-0502 following intravenous administration.

  • Fig. 4 Semilogarithmic graph depicting the plasma concentration time curves of VP-0502 (○) and VP-0502AL (●) following oral administration of VP-0502AL.

  • Fig. 5 Semilogarithmic graph depicting the plasma concentration time curves of VP-0502 (○) and VP-0502AL (●) following intravenous administration of VP-0502AL.


Reference

1. Abe Y, Shibata H, Kamada H, Tsunoda S, Tsutsumi Y, Nakagawa S. Promotion of optimized protein therapy by bioconjugation as a polymeric DDS. Anticancer Agents Med Chem. 2006. 6:251–258.
Article
2. Arnold E, Das K, Ding J, Yadav PN, Hsiou Y, Boyer PL, Hughes SH. Targeting HIV reverse transcriptase for anti-AIDS drug design: structual and biological consideration for chemotherapeutic strategies. Drug Des Discov. 1996. 13:29–47.
3. Bardsley-Elliot A, Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Paediatr Drugs. 2000. 2:373–407.
4. Cho HJ, Choi KA, Sung JM, Jeong SM, Han JS, Kim JS, Shin HC. Pharmacokinetics of a new anti-HIV agent VP-0501 and development of its amino acid prodrug for improving oral bioavailability. Korean J Vet Res. 2006. 46:7–12.
5. Dannenfelser RM, He H, Joshi Y, Bateman S, Serajuddin AT. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci. 2004. 93:1165–1175.
Article
6. Kondo N, Iwao T, Hirai K, Fukuda M, Yamanouchi K, Yokoyama K, Miyaji M, Ishihara Y, Kon K, Ogawa Y, Mayumi T. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci. 1994. 83:566–570.
Article
7. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS Pharm Sci Tech. 2006. 7:E1–E9.
8. Lin JH, Storey DE, Chen IW, Xu X. Improved oral absorption of L-365; 260:a poorly soluble drug. Biopharm Drug Dispos. 1996. 17:1–15.
9. Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, Hilfinger JM, Townsend LB, Drach JC, Amidon GL. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl) benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther. 2005. 314:883–890.
Article
10. Song X, Vig BS, Lorenzi PL, Drach JC, Townsend LB, Amidon GL. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl) benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem. 2005. 48:1274–1277.
Article
11. Sridevi S, Chauhan AS, Chalasani KB, Jain AK, Diwan PV. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-beta-cyclodextrin. Pharmazie. 2003. 58:807–810.
12. Sriram D, Yogeeswari P, Srichakravarthy N, Bal TR. Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Bioorg Med Chem Lett. 2004. 14:1085–1087.
Article
13. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull. 2004. 27:1993–1999.
Article
14. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994. 243:369–387.
Article
15. Tansey W, Ke S, Cao XY, Pasuelo MJ, Wallace S, Li C. Synthesis and characterization of branched poly (L-glutamic acid) as a biodegradable drug carrier. J Control Release. 2004. 94:39–51.
Article
16. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res. 2003. 20:1381–1388.
Full Text Links
  • JVS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr